R&D Pipeline

R&D Pipeline(In-House)

As of August 2017

Development
Stage
Product name/
Generic name/
Development Code
Development Classification Therapeutic Target
NDA Budesonide/
AJG511
In-licensed /
Co-development with EA Pharma (Japan)

Ulcerative colitis
- A locally-active steroid -
- Rectal foam product -

NDA
preparation
Vibegron/
KRP-114V
In-licensed /
Co-development with KYORIN Pharmaceutical (Japan)

Overactive bladder
- Beta 3 adrenergic receptor agonist -

Phase III Rovatirelin/
KPS-0373
In-licensed /
Shionogi (Japan)

Spinocerebellar ataxia
- Product mimetic of TRH action -

CarotegrastMethyl/
AJM300
In-licensed /
Co-development with EA Pharma (Japan)

Ulcerative colitis
- Alpha 4 integrin antagonist -

JR-131 In-licensed /
Co-development with JCR Pharmaceuticals (Japan)

Renal anemia
- Increase the red blood cell (RBC) count -
-A biosimilar "darbepoetin alfa" -

Phase II KLH-2109 Kissei

Endometriosis / Uterine fibroids
- GnRH antagonist -

Difelikefalin/
MR13A9
In-licensed /
Co-development with Maruishi Pharmaceutical (Japan)

Uremic pruritus in dialysis patients
- Kappa opioid receptor agonist-

Phase I / II YS110 In-licensed /
Y's AC, University of Tokyo, AMED (Japan)

Malignant mesothelioma
- Humanized anti-CD26 monoclonal antibody -

Phase I KDT-3594 Kissei

Parkinson's disease
- Dopamine receptor stimulation -





R&D Pipeline(Out-Licensing)

As of August 2017

Development Stage Generic name
/Development Code
Development Company Territory Therapeutic Target
NDA Mitiglinide Eisai(Japan) ASEAN 1 Type 2 diabetes mellitus
Silodosin Eisai(Japan) ASEAN, India, SriLanka 2 Dysuria associated with benign prostatic hyperplasia
Phase III KLH-2109 ObsEva SA (Switzerland) Worldwide, excluding some countries in Asia such as Japan

Uterine fibroids
- GnRH antagonist -

Phase II Bedoradrine MediciNova(U.S.) Worldwide, except for Japan

Acute exacerbation of asthma /
Preterm labor

KLH-2109 ObsEva SA (Switzerland) Worldwide, excluding some countries in Asia such as Japan

Endometriosis
- GnRH antagonist -

Phase I Bedoradrine MediciNova(U.S.) Worldwide, except for Japan COPD


1: Launched in Thailand, the Philippines, Cambodia, Myanmar ; NDA in 2 countries
2: Launched in Thailand, India, Indonesia, the Philippines, Cambodia ; Approved in Myanmar ; NDA in 3 ASEAN countries